Antoinette Verbeek-de Kanter's research while affiliated with Haaglanden Medisch Centrum and other places

... Previous research indicated stable cognitive performance up to 9 months after SRS at group-level, while almost 40% showed declined performance on the individual level. 19,20 Despite significant progress, many studies had limited follow-up durations and small sample sizes. Hence, it is crucial to confirm and continue to build upon previous findings. ...

... Pseudoprogression can be associated with new symptoms but usually is asymptomatic [34]. While pseudoprogression is most recognized in gliomas patients after conventionally fractionated RT [34], a temporary treatment-related increase in treated site can also be seen after SRS treatment of benign [35] and malignant entities [36,37]. ...

... Baseline sociodemographic and clinical characteristics are shown in Table 1. In total 36 patients (19 male) finished the 3-months follow-up NCA at a median of 16 weeks from baseline (IQR [14][15][16][17]. Median long-term follow-up time was 61 weeks from baseline (IQR 52-76). ...

... Accurate segmentation of tumour on MRI is a prerequisite for all these methods. Wiggenraad et al. have investigated the use of cine-loops for monitoring tumour size changes in brain metastasis after SRT to identify pseudo-progression (ARE) [55]. They created the cine-loops for ten patients using the axial slice with largest tumour diameter on pre-treatment contrast-enhanced T1-weighted MRI and the corresponding slices in the co-registered follow-up images. ...

... Before each fraction, daily cone beam CT was performed for the setup verification. The number of fractions, dose per fraction were chosen based on previously approved clinical trials and guidelines [13,14]. Treatment planning was carried out using multi arc non coplanar VMAT with a single isocentre to produce high quality plans with less treatment time (Fig. 1,2). ...

... The use of volumetric criteria was also discussed by the RANO-BM working group, which concluded that the 3D analysis could be unfeasible in all treatment centers due to its cost and complexity and suggested that future trials should investigate the role of these criteria in assessing disease progression [9]. Therefore, given the need to demonstrate the subgroup of patients with BM that would benefit the most from SRS, the main objective of this study is to investigate potential predictors of treatment failure in patients with a single BM secondary to NSCLC [18][19][20]. Additionally, as the value of volumetric criteria in the identification of intracranial disease progression is still unclear, the secondary objective is to assess the value of volumetric criteria in assessing BM progression when compared to the unidimensional criteria. ...